Hepatokines and Adipokines in Metabolic Syndrome

Alpana Mukhuty; Samim Ali Mondal; Satinath Mukhopadhyay

doi:10.1055/s-0042-1760087

Annals of the National Academy of Medical Sciences (India), Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Ann Natl Acad Med Sci 2023; 59(01): 004-012
DOI: 10.1055/s-0042-1760087

Review Article

Hepatokines and Adipokines in Metabolic Syndrome

Autor*innen

Alpana Mukhuty

¹Cell Signalling Laboratory, Department of Zoology, Visva-Bharati University, Santiniketan, India
Samim Ali Mondal

²Department of Ageing & Metabolism, Oklahoma Medical Research Foundation (OMRF), Oklahoma City, Oklahoma, United States
Satinath Mukhopadhyay

³Department of Endocrinology & Metabolism, Institute of Post-Graduate Medical Education & Research-Seth Sukhlal Karnani Memorial Hospital (IPGME&R-SSKM), Kolkata, India

Abstract

Hepatokines and adipokines are secretory proteins derived from hepatocytes and adipocytes, respectively. These proteins play a main role in the pathogenesis of metabolic syndrome (MetS), characterized by obesity, dysglycemia, insulin resistance, dyslipidemia, and hypertension. Adipose tissue and liver are important endocrine organs because they regulate metabolic homeostasis as well as inflammation because they secrete adipokines and hepatokines, respectively. These adipokines and hepatokines communicate their action through different autocrine, paracrine and endocrine pathways. Liver regulates systemic homeostasis and also glucose and lipid metabolism through hepatokines. Dysregulation of hepatokines can lead to progression toward MetS, type 2 diabetes (T2D), inflammation, hypertension, and other diseases. Obesity is now a worldwide epidemic. Increasing cases of obesity and obesity-associated metabolic syndrome has brought the focus on understanding the biology of adipocytes and the mechanisms occurring in adipose tissue of obese individuals. A lot of facts are now available on adipose tissue as well. Adipose tissue is now given the status of an endocrine organ. Recent evidence indicates that obesity contributes to systemic metabolic dysfunction. Adipose tissue plays a significant role in systemic metabolism by communicating with other central and peripheral organs via the production and secretion of a group of proteins known as adipokines. Adipokine levels regulate metabolic state of our body and are potent enough to have a direct impact upon energy homeostasis and systemic metabolism. Dysregulation of adipokines contribute to obesity, T2D, hypertension and several other pathological changes in various organs. This makes characterization of hepatokines and adipokines extremely important to understand the pathogenesis of MetS. Hepatokines such as fetuin-A and leukocyte cell-derived chemotaxin 2, and adipokines such as resistin, leptin, TNF-α, and adiponectin are some of the most studied proteins and they can modulate the manifestations of MetS. Detailed insight into the function and mechanism of these adipokines and hepatokines in the pathogenesis of MetS can show the path for devising better preventative and therapeutic strategies against this present-day pandemic.

Keywords

metabolic syndrome - hepatokine - adipokine - type 2 diabetes - obesity - hypertension

Volltext

Referenzen

References
1 Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28 (04) 629-636
2 DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14 (03) 173-194
3 Organization WH. Definition, diagnosis and classification of diabetes mellitus and its complications : report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. Accessed November 27, 2011, at: https://apps.who.int/iris/handle/10665/66040
4 Balkau B, Charles MA. European Group for the Study of Insulin Resistance (EGIR). Comment on the provisional report from the WHO consultation. Diabet Med 1999; 16 (05) 442-443
5 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285 (19) 2486-2497
6 Florez H, Silva E, Fernández V. et al. Prevalence and risk factors associated with the metabolic syndrome and dyslipidemia in White, Black, Amerindian and Mixed Hispanics in Zulia State, Venezuela. Diabetes Res Clin Pract 2005; 69 (01) 63-77
7 Marquezine GF, Oliveira CM, Pereira AC, Krieger JE, Mill JG. Metabolic syndrome determinants in an urban population from Brazil: social class and gender-specific interaction. Int J Cardiol 2008; 129 (02) 259-265
8 Phillips SA, Ciaraldi TP, Oh DK, Savu MK, Henry RR. Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. Am J Physiol Endocrinol Metab 2008; 295 (04) E842-E850
9 Reaven GM. Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension. Parallels between human disease and rodent models. Diabetes Care 1991; 14 (03) 195LP-202
10 Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31 (09) 1898-1904
11 Murakami T, Michelagnoli S, Longhi R. et al. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol 1995; 15 (11) 1819-1828
12 Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22 (01) 11-19
13 Takata Y, Osawa H, Kurata M. et al. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertens (Dallas, Tex 1979) 2008; 51 (02) 534-539
14 He J, Whelton PK. Epidemiology and prevention of hypertension. Med Clin North Am 1997; 81 (05) 1077-1097
15 Oral EA, Simha V, Ruiz E. et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346 (08) 570-578
16 Farooqi IS, Jebb SA, Langmack G. et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341 (12) 879-884
17 Lamers D, Famulla S, Wronkowitz N. et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011; 60 (07) 1917-1925
18 Sell H, Blüher M, Klöting N. et al. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care 2013; 36 (12) 4083-4090
19 El Husseny MWA, Mamdouh M, Shaban S. et al. Adipokines: potential therapeutic targets for vascular dysfunction in type II diabetes mellitus and obesity. J Diabetes Res 2017; 2017: 8095926
20 Way JM, Görgün CZ, Tong Q. et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2001; 276 (28) 25651-25653
21 Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002; 13 (01) 18-23
22 Silha JV, Murphy LJ. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2004; 89 (04) 1977 , author reply 1977–1978
23 Satoh H, Nguyen MTA, Miles PDG, Imamura T, Usui I, Olefsky JM. Adenovirus-mediated chronic “hyper-resistinemia” leads to in vivo insulin resistance in normal rats. J Clin Invest 2004; 114 (02) 224-231
24 Lu HL, Wang HW, Wen Y, Zhang MX, Lin HH. Roles of adipocyte derived hormone adiponectin and resistin in insulin resistance of type 2 diabetes. World J Gastroenterol 2006; 12 (11) 1747-1751
25 Jørgensen SB, Honeyman J, Oakhill JS. et al. Oligomeric resistin impairs insulin and AICAR-stimulated glucose uptake in mouse skeletal muscle by inhibiting GLUT4 translocation. Am J Physiol Endocrinol Metab 2009; 297 (01) E57-E66
26 Zhang Y, Li Y, Yu L, Zhou L. Association between serum resistin concentration and hypertension: A systematic review and meta-analysis. Oncotarget 2017; 8 (25) 41529-41537
27 Mohamed-Ali V, Goodrick S, Rawesh A. et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82 (12) 4196-4200
28 Weigert C, Lehmann R, Schleicher ED. Point-counterpoint: interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 2007; 102 (02) 820-821 , author reply 825
29 Sabio G, Das M, Mora A. et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008; 322 (5907): 1539-1543
30 Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007; 56 (04) 1010-1013
31 Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280 (05) E745-E751
32 Al-Khalili L, Bouzakri K, Glund S, Lönnqvist F, Koistinen HA, Krook A. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 2006; 20 (12) 3364-3375
33 Gomez-Huelgas R, Ruiz-Nava J, Santamaria-Fernandez S. et al. Impact of intensive lifestyle modification on levels of adipokines and inflammatory biomarkers in metabolically healthy obese women. Mediators Inflamm 2019; 2019: 4165260
34 Després J-P, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444 (7121): 881-887
35 Cai D, Yuan M, Frantz DF. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11 (02) 183-190
36 Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389 (6651): 610-614
37 Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43 (11) 1271-1278
38 Souza SC, Palmer HJ, Kang YH. et al. TNF-alpha induction of lipolysis is mediated through activation of the extracellular signal related kinase pathway in 3T3-L1 adipocytes. J Cell Biochem 2003; 89 (06) 1077-1086
39 Kumari R, Kumar S, Ahmad MK. et al. TNF-α/IL-10 ratio: An independent predictor for coronary artery disease in North Indian population. Diabetes Metab Syndr 2018; 12 (03) 221-225
40 Hara K, Boutin P, Mori Y. et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002; 51 (02) 536-540
41 Yamauchi T, Kamon J, Waki H. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7 (08) 941-946
42 Yamauchi T, Kamon J, Minokoshi Y. et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8 (11) 1288-1295
43 Heidemann C, Sun Q, van Dam RM. et al. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 2008; 149 (05) 307-316
44 Ouchi N, Kihara S, Arita Y. et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103 (08) 1057-1063
45 Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271 (18) 10697-10703
46 Bacha F, Saad R, Gungor N, Arslanian SA. Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care 2004; 27 (02) 547-552
47 Varshney R, Varshney R, Mishra R, Gupta S, Sircar D, Roy P. Kaempferol alleviates palmitic acid-induced lipid stores, endoplasmic reticulum stress and pancreatic β-cell dysfunction through AMPK/mTOR-mediated lipophagy. J Nutr Biochem 2018; 57: 212-227
48 Foula WH, Emara RH, Eldeeb MK, Mokhtar SA, El-Sahn FA. Effect of a weight loss program on serum adiponectin and insulin resistance among overweight and obese premenopausal females. J Egypt Public Health Assoc 2020; 95 (01) 32
49 Ma W, Huang T, Zheng Y. et al. Weight-loss diets, adiponectin, and changes in cardiometabolic risk in the 2-Year POUNDS lost trial. J Clin Endocrinol Metab 2016; 101 (06) 2415-2422
50 Silva FM, de Almeida JC, Feoli AM. Effect of diet on adiponectin levels in blood. Nutr Rev 2011; 69 (10) 599-612
51 Wang X, You T, Murphy K, Lyles MF, Nicklas BJ. Addition of exercise increases plasma adiponectin and release from adipose tissue. Med Sci Sports Exerc 2015; 47 (11) 2450-2455
52 Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne) 2019; 10: 155
53 Hartman ML, Sanyal AJ, Loomba R. et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care 2020; 43 (06) 1352-1355
54 Ochi A, Mori K, Emoto M. et al. Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression. PLoS One 2014; 9 (02) e88704
55 Miyazaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab 2008; 10 (12) 1204-1211
56 Jazet IM, Pijl H, Meinders AE. Adipose tissue as an endocrine organ: impact on insulin resistance. Neth J Med 2003; 61 (06) 194-212
57 Münzberg H, Myers Jr MGJ. Molecular and anatomical determinants of central leptin resistance. Nat Neurosci 2005; 8 (05) 566-570
58 Becker DJ, Ongemba LN, Brichard V, Henquin JC, Brichard SM. Diet- and diabetes-induced changes of ob gene expression in rat adipose tissue. FEBS Lett 1995; 371 (03) 324-328
59 Morris DL, Rui L. Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab 2009; 297 (06) E1247-E1259
60 Sima E, Webb DL, Hellström PM, Sundbom M. Non-responders after dastric bypass surgery for morbid obesity: peptide hormones and glucose homeostasis. Obes Surg 2019; 29 (12) 4008-4017
61 Obradovic M, Sudar-Milovanovic E, Soskic S. et al. Leptin and obesity: role and clinical implication. Front Endocrinol (Lausanne) 2021; 12 (May): 585887
62 Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011; 54 (10) 2506-2514
63 Lean ME, Leslie WS, Barnes AC. et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391 (10120): 541-551
64 Minokoshi Y, Kim Y-B, Peroni OD. et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002; 415 (6869): 339-343
65 Shalitin S, Phillip M. Role of obesity and leptin in the pubertal process and pubertal growth–a review. Int J Obes Relat Metab Disord 2003; 27 (08) 869-874
66 Iroz A, Couty J-P, Postic C. Hepatokines: unlocking the multi-organ network in metabolic diseases. Diabetologia 2015; 58 (08) 1699-1703
67 Gastaldelli A, Stefan N, Häring H-U. Liver-targeting drugs and their effect on blood glucose and hepatic lipids. Diabetologia 2021; 64 (07) 1461-1479
68 Oh KJ, Lee DS, Kim WK, Han BS, Lee SC, Bae K-H. Metabolic adaptation in obesity and type II diabetes: myokines, adipokines and hepatokines. Int J Mol Sci 2016; 18 (01) E8
69 Jung TW, Yoo HJ, Choi KM. Implication of hepatokines in metabolic disorders and cardiovascular diseases. BBA Clin 2016; 5: 108-113
70 Choi KM, Han KA, Ahn HJ. et al. The effects of caloric restriction on fetuin-A and cardiovascular risk factors in rats and humans: a randomized controlled trial. Clin Endocrinol (Oxf) 2013; 79 (03) 356-363
71 Malin SK, del Rincon JP, Huang H, Kirwan JP. Exercise-induced lowering of fetuin-A may increase hepatic insulin sensitivity. Med Sci Sports Exerc 2014; 46 (11) 2085-2090
72 Wu H-T, Ou H-Y, Hung H-C. et al. A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes. Diabetologia 2016; 59 (08) 1732-1742
73 Mashili FL, Austin RL, Deshmukh AS. et al. Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab Res Rev 2011; 27 (03) 286-297
74 Fisher FM, Kleiner S, Douris N. et al. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev 2012; 26 (03) 271-281
75 Berti L, Irmler M, Zdichavsky M. et al. Fibroblast growth factor 21 is elevated in metabolically unhealthy obesity and affects lipid deposition, adipogenesis, and adipokine secretion of human abdominal subcutaneous adipocytes. Mol Metab 2015; 4 (07) 519-527
76 Reinehr T, Karges B, Meissner T. et al. Inflammatory markers in obese adolescents with type 2 diabetes and their relationship to hepatokines and adipokines. J Pediatr 2016; 173: 131-135
77 Semba RD, Crasto C, Strait J, Sun K, Schaumberg DA, Ferrucci L. Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults. J Hum Hypertens 2013; 27 (06) 397-399
78 Ebert T, Kralisch S, Loessner U. et al. Relationship between serum levels of angiopoietin-related growth factor and metabolic risk factors. Horm Metab Res = Horm und Stoffwechselforsch = Horm Metab 2014; 46 (10) 685-690
79 Yang SJ, Hwang SY, Choi HY. et al. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrinol Metab 2011; 96 (08) E1325-E1329
80 Gharipour M, Sadeghi M, Salehi M. et al. Association of expression of selenoprotein P in mRNA and protein levels with metabolic syndrome in subjects with cardiovascular disease: results of the Selenegene study. J Gene Med 2017; 19 (03)
81 Jung TW, Choi HY, Lee SY. et al. Salsalate and adiponectin improve palmitate-induced insulin resistance via inhibition of selenoprotein P through the AMPK-FOXO1α pathway. PLoS One 2013; 8 (06) e66529
82 Misu H, Ishikura K, Kurita S. et al. Inverse correlation between serum levels of selenoprotein P and adiponectin in patients with type 2 diabetes. PLoS One 2012; 7 (04) e34952
83 Mandard S, Zandbergen F, van Straten E. et al. The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J Biol Chem 2006; 281 (02) 934-944
84 Xu A, Lam MC, Chan KW. et al. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci U S A 2005; 102 (17) 6086-6091
85 Yin Y, Ding X, Peng L. et al. Increased serum ANGPTL8 concentrations in patients with prediabetes and Type 2 diabetes. J Diabetes Res 2017; 2017: 8293207
86 Abu-Farha M, Cherian P, Qaddoumi MG. et al. Increased plasma and adipose tissue levels of ANGPTL8/betatrophin and ANGPTL4 in people with hypertension. Lipids Health Dis 2018; 17 (01) 35
87 Lan F, Misu H, Chikamoto K. et al. LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance. Diabetes 2014; 63 (05) 1649LP-1664
88 Hwang HJ, Jung TW, Kim BH. et al. A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression. Biochem Pharmacol 2015; 98 (01) 157-166